Peng Guo (P Guo)

ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 10

Top Venues

Science advances

Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Nano letters

ACS biomaterials science & engineering

Children's Hospital Boston

University of Florida (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Children's Hospital Boston

United States

Instructor :: Vascular Biology Program

Children's Hospital Boston

United States

Research Fellow :: Vascular Biology Program

City College of New York

United States

Research Associate :: Biomedical Engineering

Harvard University

United States

Postdoctoral Researcher :: School of Engineering and Applied Sciences

Education History

University of Florida Sep 01 2006 - May 01 2011

United States

PHD :: Chemistry

Publications

Peng Zhang, Changjuan Tao, Ye Lu, Peijing Li, Xing Wang, Yujie Dai, Yun Xi, Takaya Shimura, Xinfang Li, Jianmin Fang, Liu Yang, Dawei He, Peng Guo
Epigenetic Reprogramming Potentiates ICAM1 Antibody Drug Conjugates in Preclinical Models of Melanoma. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 11 (30) (2024)
Peng Zhang, Changjuan Tao, Ye Lu, Peijing Li, Xing Wang, Yujie Dai, Yun Xi, Takaya Shimura, Xinfang Li, Jianmin Fang, Liu Yang, Dawei He, Peng Guo
Epigenetic Reprogramming Potentiates ICAM1 Antibody Drug Conjugates in Preclinical Models of Melanoma. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 11 (30) (2024)
Peng Zhang, Changjuan Tao, Ye Lu, Peijing Li, Xing Wang, Yujie Dai, Yun Xi, Takaya Shimura, Xinfang Li, Jianmin Fang, Liu Yang, Dawei He, Peng Guo
Epigenetic Reprogramming Potentiates ICAM1 Antibody Drug Conjugates in Preclinical Models of Melanoma. Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2024)
Peng Guo, Jing Huang, Bing Zhu, Andrew C Huang, Lingxiao Jiang, Jianmin Fang, Marsha A Moses
A rationally designed ICAM1 antibody drug conjugate eradicates late-stage and refractory triple-negative breast tumors in vivo. Science advances 9 (18) (2023)
Peng Guo, Jing Huang, Bing Zhu, Andrew C Huang, Lingxiao Jiang, Jianmin Fang, Marsha A Moses
A rationally designed ICAM1 antibody drug conjugate eradicates late-stage and refractory triple-negative breast tumors in vivo. Science advances 9 (18) (2023)
Peng Guo, Jing Huang, Bing Zhu, Andrew C Huang, Lingxiao Jiang, Jianmin Fang, Marsha A Moses
A rationally designed ICAM1 antibody drug conjugate eradicates late-stage and refractory triple-negative breast tumors in vivo. Science advances 9 (18) (2023)
Peng Guo, Jing Huang, Bing Zhu, Andrew C Huang, Lingxiao Jiang, Jianmin Fang, Marsha A Moses
A rationally designed ICAM1 antibody drug conjugate eradicates late-stage and refractory triple-negative breast tumors in vivo. Science advances 9 (18) (2023)
Jing Huang, Peng Guo, Marsha A Moses
Rationally Designed Antibody Drug Conjugates Targeting the Breast Cancer-Associated Endothelium. ACS biomaterials science & engineering 6 (5) (2019)
Peng Guo, Jing Huang, Yaping Zhao, Charles R Martin, Richard N Zare, Marsha A Moses
Nanomaterial Preparation by Extrusion through Nanoporous Membranes. Small (Weinheim an der Bergstrasse, Germany) 14 (18) (2018)
Peng Guo, B Wang, D Liu, J Yang, K Subramanyam, C R McCarthy, J Hebert, M A Moses, D T Auguste
Using Atomic Force Microscopy to Predict Tumor Specificity of ICAM1 Antibody-Directed Nanomedicines. Nano letters 18 (4) (2018)

Peng Guo.css-eqlu8i{font-size:small;padding-left:4px;} (P Guo)

Publication Activity (10 Years)

Top Topics

Top Venues

Peng Guo (P Guo)